Streetbeat News

Products Services

BTCY

Biotricity Inc. (NASDAQ:BTCY) announced the expansion of its Cardiac AI Cloud platform, leveraging advancements in AI to improve operational efficiency and margins. The company is developing a cardiac AI clinical model to support clinical decisions, with plans to file for FDA clearance by year-end. The healthcare AI market is expected to reach $208.2 billion by 2030, with remote patient monitoring anticipated to hit $96.67 billion. Biotricity's expansion includes partnerships with Google's TensorFlow and Amazon Web Services, aiming to enhance diagnostic accuracy and patient outcomes through predictive analytics and the analysis of over 500 billion heartbeats.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:04 pm

BYDDY

TSLA

XIACF

BYD (OTC:BYDDY) and Xiaomi (OTC:XIACF) are intensifying competition in the EV market by focusing on making electric vehicles more affordable, aiming to outcompete gasoline vehicles. BYD has surpassed Tesla (NASDAQ:TSLA) as the largest EV manufacturer globally and is updating its technology to lower prices further. Xiaomi is entering the EV market with its SU7 sedan, ready to join the price war. This aggressive pricing strategy is leading to a broader adoption of EVs in China, though it's also causing a decline in deliveries for major players like BYD and Tesla.

Portfolio Pulse from Benzinga Neuro

March 12, 2024 | 1:04 pm

BA

UAL

United Airlines Holdings' CEO announced plans to convert to Max 10s pending certification. This move indicates a strategic shift towards newer, potentially more efficient aircraft models.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:03 pm

WKHS

Workhorse Group has announced that due to numerous key customer demonstrations planned for Q1 2024, it will not provide specific annual revenue or unit guidance at this time. The company will report on its progress as it occurs.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:03 pm

GNPX

Genprex has been granted a Korean patent for its Reqorsa Immunogene Therapy in combination with PD-1 and PD-L1 antibodies for cancer treatment. This development could enhance Genprex's intellectual property portfolio and potentially boost its position in the global oncology market.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:03 pm

WKHS

Workhorse Group is finalizing a workforce reduction of approximately 20%, excluding direct labor, as part of cost-cutting measures to strengthen its financial position. The company is in negotiations for financing to provide a financial runway and is transitioning its Aero business to a DaaS model, which includes stopping drone production and development and terminating related employees. Executive officers have agreed to defer 20% of their cash compensation for at least three months.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:02 pm

VEEV

17 analysts have recently shared their evaluations of Veeva Systems (NYSE:VEEV), showing a mix of bullish and bearish sentiments. The average 12-month price target is $241.06, reflecting a 12.03% increase from the previous target of $215.18. Analysts from firms like Morgan Stanley, Keybanc, and Jefferies have adjusted their ratings and price targets, indicating a positive outlook for VEEV. The company, a leading provider of cloud-based solutions for the life sciences industry, has shown impressive financial performance with significant revenue growth, high net margin, and strong ROE and ROA, despite lagging behind its industry peers in revenue growth rate.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 1:00 pm

KA

MRK

Kineta's shares surged following an update on its VISTA-101 Phase 1/2 clinical trial for KVA12123, both as a monotherapy and combined with Merck's KEYTRUDA, targeting advanced solid tumors.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:00 pm

ICU

SeaStar Medical Holding Corporation (NASDAQ:ICU) provided updates on its acute kidney injury (AKI) programs, including the enrollment of 21 subjects in its NEUTRALIZE-AKI clinical trial for adult AKI patients. The trial aims to enroll up to 200 adults to evaluate the safety and efficacy of its Selective Cytopheretic Device (SCD) therapy. Additionally, the FDA granted a Humanitarian Device Exemption Approval Order for its Quelimmune pediatric device for AKI due to sepsis, with plans to expand commercial rollout with Nuwellis, Inc. in Q2. The company also plans a business update conference call in April.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:57 pm

ICCT

iCoreConnect Inc. has entered into a strategic partnership with Carestream Dental. This collaboration aims to enhance dental practices by integrating Rx Manager with Carestream's systems, offering streamlined workflows, improved user experiences, and scalable solutions adaptable to any business size.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:57 pm